Monday December 18, 2017 0 comments
ENGLEWOOD -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the appointment of David A. Green as chief financial officer.
Green is a highly accomplished CFO with an extensive array of financial, accounting, and operational experience, including a background at both public and private life sciences companies over his 25-year career.
Green will oversee Aytu's finance and accounting functions and will report directly to the CEO.
Prior to joining Aytu, Green served as chief accounting officer at Intarcia Therapeutics, a biopharmaceutical company currently engaged in late stage clinical development.
Before that, he was CFO of Catheter Connections, a commercial-stage medical device company that was acquired by Merit Medical.
Green has also served as CFO at Specialized Health Products International, a publicly traded medical device company that was acquired by C.R. Bard.
Green earned a Bachelor of Science from the State University of New York, a Master of Business Administration from the University of Rochester, and is a Certified Public Accountant.
"Dave's deep experience in finance, accounting and operations at high-growth, commercial-stage life sciences companies, along with his extensive transactional, valuation, and strategic planning expertise make him an excellent addition to Aytu's senior leadership team at this important stage of the company's growth," said Josh Disbrow, Aytu’s CEO.
"Dave's extensive background as a public company CFO, paired with his experience across numerous transactions during his investment banking career, will be valuable to Aytu as we continue to grow by increasing sales of our current portfolio of products, as well as through additional strategic transactions.
“I welcome Dave and look forward to his contributions as a key member of our leadership team."
"I am excited to be joining Josh and his talented leadership team at Aytu, and believe the company is well positioned for tremendous value creation as we continue toward our objective of building a leading specialty life sciences company with substantial prospects for growth," said Green.